RSV vaccine study for high-risk children
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Children aged 5 to under 18 years old.
- Must have a chronic medical condition like asthma, cystic fibrosis, Down syndrome, or heart disease, or an immunocompromising condition like a transplant or immune deficiency.
- Must meet minimum weight requirements (14.5 kg for ages 5–11, 30 kg for ages 12–17).
- No history of severe allergic reaction to vaccines, uncontrolled seizures, bleeding disorders, or Guillain-Barré syndrome.
- Not pregnant.
- Parent or guardian must give consent, and the child must agree to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.